Nintedanib Teva (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases, including VEGFR, PDGFR and FGFR. Inhibition of these pathways reduces fibroblast activation, migration and extracellular matrix production, thereby limiting the formation of scar tissue in the lungs.

The prescribed dose of Nintedanib Teva is determined by the treating physician based on the patient’s clinical condition, renal and hepatic function, and other individual factors. The prescribing information provides detailed dosing guidance that the prescriber will follow.

Data on the use of Nintedanib during pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative antifibrotic agent is pirfenidone. Both drugs aim to slow lung‑fibrosis progression, but they differ in molecular targets, side‑effect profiles and dosing regimens. Nintedanib’s multi‑kinase inhibition may offer broader antifibrotic activity, while pirfenidone primarily modulates inflammatory pathways.

Store the tablets at room temperature, below 25 °C, in the original blister pack or container. Protect them from excess moisture, heat and direct sunlight to maintain product stability throughout its shelf life.

Nintedanib Teva is taken orally, usually with food to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious adverse events include liver enzyme elevations, significant bleeding, cardiovascular complications such as myocardial infarction, severe infections, gastrointestinal perforations, and rare skin reactions like Stevens‑Johnson syndrome. Patients should report any unusual symptoms promptly to their physician.

Nintedanib is contraindicated in patients with known hypersensitivity to the active substance or any of its excipients. Caution is advised for individuals with severe hepatic impairment, uncontrolled bleeding disorders, or those taking strong CYP3A4 or P‑gp inhibitors. The prescriber will assess suitability on a case‑by‑case basis.